Haemate P

Haemate P is a lyophilized powder for solution for injection that contains human coagulation factor VIII and human von Willebrand factor. It is supplied without a specified strength and is administered intravenously under prescription. The product is classified as a coagulation factor replacement and is used in the European market for managing bleeding disorders such as hemophilia A and von Willebrand disease in clinical practice.

Haemate P is indicated for several therapeutic situations related to deficient clotting factors.

- Treatment of hemophilia A, including patients with and without inhibitors. - Management of von Willebrand disease type 3. - Surgical prophylaxis to prevent bleeding in patients with hemophilia A undergoing invasive procedures. - On-demand treatment of acute bleeding episodes in individuals with factor VIII or von Willebrand factor deficiency. - Long‑term prophylactic therapy to reduce the frequency of spontaneous bleeds in severe hemophilia A.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common: - Mild pain, redness, or swelling at the injection site. - Transient headache lasting a few hours. - Low‑grade fever (temperature <38.5 °C) shortly after infusion. - Nausea or occasional vomiting during or after administration. - Minor skin rash or itching without systemic involvement.

Serious: - Anaphylactic or severe hypersensitivity reactions requiring emergency treatment. - Development of neutralizing antibodies (inhibitors) against factor VIII, reducing efficacy. - Thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism. - Acute renal impairment linked to infusion‑related events.

When prescribing Haemate P, clinicians should consider several precautionary measures to ensure safe use.

- Assess patient history for prior allergic reactions to plasma‑derived products. - Monitor for the emergence of factor VIII inhibitors, especially in previously untreated patients. - Evaluate renal and hepatic function before initiating therapy and periodically during treatment. - Use caution in patients with a history of thromboembolic disease or cardiovascular risk factors. - Adjust dosing in pediatric patients and in individuals with severe bleeding phenotypes. - Ensure proper aseptic technique during reconstitution and intravenous administration.

Haemate P may interact with other medications or biologics, influencing efficacy or safety.

Avoid: - Concurrent use of other plasma‑derived clotting factor concentrates without medical supervision. - Administration with investigational gene‑therapy products targeting factor VIII or von Willebrand factor. - Simultaneous infusion of high‑dose immunoglobulins that could interfere with factor activity assays.

Use with caution: - Antifibrinolytic agents (e.g., tranexamic acid) may increase clot stability; monitor for thrombosis. - Immunosuppressive drugs that could affect inhibitor development; observe inhibitor titers. - Concomitant use of anticoagulants (e.g., warfarin, direct oral anticoagulants) may require dose adjustments and close monitoring.